Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation

Duloxetine hydrochloride (DH) is a serotonin–norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of depression. Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism. This study aims to develop DH buccoadhesive films to improve its bioavailability. D...

Full description

Bibliographic Details
Main Authors: Amr Mostafa El Sharawy, Marwa Hassan Shukr, Ahmed Hassen Elshafeey
Format: Article
Language:English
Published: Taylor & Francis Group 2017-01-01
Series:Drug Delivery
Subjects:
Online Access:http://dx.doi.org/10.1080/10717544.2017.1402216
id doaj-a4041f920b4147f2977484ad2f50ba77
record_format Article
spelling doaj-a4041f920b4147f2977484ad2f50ba772020-11-25T03:27:17ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642017-01-012411762176910.1080/10717544.2017.14022161402216Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluationAmr Mostafa El Sharawy0Marwa Hassan Shukr1Ahmed Hassen Elshafeey2National Organization for Drug Control and Research (NODCAR)National Organization for Drug Control and Research (NODCAR), Cairo UniversityDuloxetine hydrochloride (DH) is a serotonin–norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of depression. Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism. This study aims to develop DH buccoadhesive films to improve its bioavailability. DH buccoadhesive films were prepared adopting the solvent casting method using hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA). The prepared films were evaluated for weight uniformity, drug content, surface pH, swelling index, mucoadhesion strength and drug release percentages. Accelerated stability and bioavailability studies in healthy human volunteers were also performed for the selected films. Results of the evaluation tests showed that the optimum physicochemical characters were obtained by the films prepared with 2% HPMC using 10% propylene glycol (F2 films). Accelerated stability studies revealed that DH showed proved stability throughout the experiment time. DH bioavailability from F2 films was determined and compared with that of the marketed oral capsules (Cymbalta® 30 mg). The pharmacokinetic results showed that Cmax for F2 was higher than the market product. In addition, ANOVA analysis showed that a Tmax of F2 film was significantly lower, while, the AUC0–72 of F2 was significantly higher than that of Cymbalta capsules. The percentage relative bioavailability of DH from F2 was found to be 296.39%. Therefore, the prepared buccal films offer an alternative route for the administration of DH with the possibility of improving its bioavailability.http://dx.doi.org/10.1080/10717544.2017.1402216buccoadhesive filmsduloxetine hydrochloridemucoadhesiondrug releaseaccelerated stabilitybioavailability
collection DOAJ
language English
format Article
sources DOAJ
author Amr Mostafa El Sharawy
Marwa Hassan Shukr
Ahmed Hassen Elshafeey
spellingShingle Amr Mostafa El Sharawy
Marwa Hassan Shukr
Ahmed Hassen Elshafeey
Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation
Drug Delivery
buccoadhesive films
duloxetine hydrochloride
mucoadhesion
drug release
accelerated stability
bioavailability
author_facet Amr Mostafa El Sharawy
Marwa Hassan Shukr
Ahmed Hassen Elshafeey
author_sort Amr Mostafa El Sharawy
title Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation
title_short Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation
title_full Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation
title_fullStr Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation
title_full_unstemmed Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation
title_sort formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation
publisher Taylor & Francis Group
series Drug Delivery
issn 1071-7544
1521-0464
publishDate 2017-01-01
description Duloxetine hydrochloride (DH) is a serotonin–norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of depression. Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism. This study aims to develop DH buccoadhesive films to improve its bioavailability. DH buccoadhesive films were prepared adopting the solvent casting method using hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA). The prepared films were evaluated for weight uniformity, drug content, surface pH, swelling index, mucoadhesion strength and drug release percentages. Accelerated stability and bioavailability studies in healthy human volunteers were also performed for the selected films. Results of the evaluation tests showed that the optimum physicochemical characters were obtained by the films prepared with 2% HPMC using 10% propylene glycol (F2 films). Accelerated stability studies revealed that DH showed proved stability throughout the experiment time. DH bioavailability from F2 films was determined and compared with that of the marketed oral capsules (Cymbalta® 30 mg). The pharmacokinetic results showed that Cmax for F2 was higher than the market product. In addition, ANOVA analysis showed that a Tmax of F2 film was significantly lower, while, the AUC0–72 of F2 was significantly higher than that of Cymbalta capsules. The percentage relative bioavailability of DH from F2 was found to be 296.39%. Therefore, the prepared buccal films offer an alternative route for the administration of DH with the possibility of improving its bioavailability.
topic buccoadhesive films
duloxetine hydrochloride
mucoadhesion
drug release
accelerated stability
bioavailability
url http://dx.doi.org/10.1080/10717544.2017.1402216
work_keys_str_mv AT amrmostafaelsharawy formulationandoptimizationofduloxetinehydrochloridebuccalfilmsinvitroandinvivoevaluation
AT marwahassanshukr formulationandoptimizationofduloxetinehydrochloridebuccalfilmsinvitroandinvivoevaluation
AT ahmedhassenelshafeey formulationandoptimizationofduloxetinehydrochloridebuccalfilmsinvitroandinvivoevaluation
_version_ 1724588500370587648